| December 3 |
Pharmacopeia Announces Additional Positive Findings from Phase 1
Multiple Ascending Dose Study of PS433540 (DARA) |
| December 3 |
Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data
Presentation Webcast and Conference Call |
| December 3 |
Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in
Breast Cancer Patients |
| December 3 |
Discovery Labs' Aerosurf Improves Lung Function and Reduces
Inflammation in a Model of Respiratory Distress Syndrome |
| December 3 |
UCB Announces New Data Showing Investigational Drug Lacosamide
Significantly Reduced Seizures in Refractory Epilepsy Patients |
| December 3 |
SuperGen to Highlight Oncology Pipeline Data in Multiple
Presentations at the American Society of Hematology's 49th Annual
Meeting |
| December 3 |
Ceragenix Announces Promising Antimicrobial Coating Data |
| December 3 |
SuperGen to Highlight Oncology Pipeline Data in Multiple
Presentations at the American Society of Hematology's 49th Annual
Meeting |
| December 3 |
MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study |
| December 3 |
Access Pharmaceuticals' ProLindac to be Featured at the 10th
International Symposium on Platinum Coordination Compounds in
Cancer Chemotherapy Conference |
| December 3 |
Merck's Rotateq Reduced Hospitalizations and Emergency Department
Visits Due to G9P1A(8) Rotavirus by 100 Percent as Shown by
Post-hoc Analysis of Data |
| December 3 |
Immunomedics to Present At American Society of Hematology 49th
Annual Meeting |
| December 3 |
Bayer AG: Review of Rivaroxaban Data Presented at the 49th Annual
Meeting of the American Society of Hematology (ASH) - Investor
Conference Call on December 11, 2007 |
| December 3 |
Callisto Announces Presentation on Guanilib at 2007 Crohn's and
Colitis Foundation National Research and Clinical Conference |
| December 3 |
Early Treatment with Copaxone Demonstrated Robust Protection
Against Progression to Clinically Definite Multiple Sclerosis in
the PreCISe Study |
| December 3 |
Targacept Announces Results of Phase II Study of TC-2696 in
Postoperative Dental Pain |
| December 3 |
Gemin X Pharmaceuticals to Present Data on Obatoclax at American
Society of Hematology Annual Meeting |
| December 3 |
Avicena Announces Positive Phase II Data for a Combination Trial
Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis
(ALS) |
| December 3 |
Intercell´s Clinical Data on Japanese Encephalitis Vaccine
Published in “the Lancet” |
| December 3 |
Aerosol Launches Immune Response in Lungs to Wipe Out Lethal
Infections |
| December 3 |
Knopp Neurosciences Presents Results of Phase 1 Ascending
Single-Dose Study of KNS-760704 |
| December 3 |
UCB Announces Positive Phase III Trial Results for Keppra XR
(levetiracetam) Extended-Release Tablets |
| December 3 |
New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory
Depressant Effects in Patients With Moderate-to-Severe COPD |
| December 4 |
Inhibiton Therapeutics Announces ICA-1 Compound Effective in
In-Vitro Testing in Various Cancer Cell Lines |
| December 4 |
Four Abstracts by Biopure and Collaborating Scientists Accepted for
Annual Meeting of American Society for Clinical Pharmacology and
Therapeutics |
| December 4 |
Soliris Demonstrates Reductions in Hemolysis and Improvements in
Fatigue, Overall Quality of Life and Anemia in a Broad Population
of PNH Patients |
| December 4 |
ZymoGenetics to Present at American Society of Hematology Annual
Meeting |
| December 4 |
ThromboGenics Presents Results of the Vitreomacular Traction Trial
(MIVI IIT) at the American Society of Retina Specialists Annual
Meeting |
| December 4 |
EpiCept Announces Presentation of New Ceplene Data at the 49th
Annual Meeting of the American Society of Hematology |
| December 4 |
Telik Announces Telintra Presentation at American Society of
Hematology Annual Meeting |
| December 4 |
Targeted Genetics Reports on Recombinant DNA Advisory Committee
(RAC) Assessment of Its Phase I/II Trial of tgAAC94 for
Inflammatory Arthritis |
| December 4 |
UCB Announces Positive Results From Phase II Clinical Trial of
Investigational Anti-Epilepsy Drug Brivaracetam |
| December 4 |
Genta Clinical Programs Featured at American Society of Hematology
Meeting |
| December 4 |
ChemGenex Announces Poster Presentations at the 49th Annual Meeting
of the American Society of Hematology |
| December 4 |
Celtic Pharma Reports Data Presented at Society for Neuro-Oncology
Annual Meeting and Provides Update on Xerecept Clinical Program |
| December 4 |
Could Hydrogen Sulfide Hold the Key to A Long Life? |
| December 4 |
Cannasat and IntelGenx Complete Phase 1 Study for CAT 310 |
| December 4 |
Study: Re-engineered Gleevec Reduces Heart Risks |
| December 5 |
113 Abstracts Evaluating Celgene Products to Be Presented at the
49th American Society of Hematology Meeting |
| December 5 |
Rigel Announces Presentations at the 2007 American Society of
Hematology (ASH) Meeting |
| December 5 |
Celtic Pharma Provides Update on XERECEPT Clinical Program |
| December 5 |
Study Data Show Asacol (Mesalamine) is Effective in Treating All
Extents of Ulcerative Colitis Including Isolated Proctitis |
| December 5 |
Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet
Primary Endpoint |
| December 5 |
Data from Innovive Pharmaceuticals' Oncology Drug Programs to be
Presented at the American Society of Hematology 49th Annual Meeting |
| December 5 |
Journal of the American Medical Association (JAMA) Publishes
One-Year Acuity Trial Results |
| December 5 |
AVANT Immunotherapeutics Achieves Immune Responses Against Cholera,
Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral
Combination Vaccine |
| December 5 |
Preliminary Results Show Lotemax with Topical Cyclosporine to be
Effective for Relief of Dry Eye Signs and Symptoms |
| December 5 |
New Data Reinforces the Superiority of Escitalopram Over Duloxetine
for Acute Treatment of Depression |
| December 5 |
Updated Analysis of 2001 Epoetin Alfa Study Posted |
| December 5 |
Drug Found to Create New Connections in Brain, Restoring and
Improving Memory |
| December 5 |
AstraZeneca Presents New Depression and Anxiety Results for
SEROQUEL XR |
| December 5 |
Soliris Demonstrates Reductions in Hemolysis and Improvements in
Fatigue, Overall Quality of Life and Anemia in a Broad Population
of Pnh Patients |
| December 5 |
Study Data Show Asacol (mesalamine) is Effective in Treating All
Extents of Ulcerative Colitis Including Isolated Proctitis |
| December 5 |
Pheromones Identified That Trigger Aggression Between Male Mice |
| December 5 |
Scientists Identify Gene That Influences Alcohol Consumption |
| December 5 |
Cyclacel Pharmaceuticals Announces Sapacitabine Poster Presentation
at Upcoming American Society of Hematology Meeting |
| December 5 |
Pharmatech, Inc. to Present Preliminary Trial Results at the
American Society of Hematology 49th Annual Meeting |
| December 6 |
Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for
Remoxy |
| December 6 |
Favrille to Report New Data on FavId (Now Specifid) at American
Society of Hematology Annual Meeting |
| December 6 |
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal
Phase II Trial of Cloretazine (VNP40101M) at the American Society
of Hematology Meeting |
| December 6 |
Pluristem to Present at the Annual Meeting of the American Society
of Hematology |
| December 6 |
Monotherapy Byetta Showed Significant Improvement in Glucose
Control and Weight Loss in Adults with Type 2 Diabetes |
| December 6 |
Data on PolyMedix's Heptagonist Compounds to be Presented at Annual
Meeting of the American Society of Hematology |
| December 6 |
ANAVEX Advances Drug Candidates for Treatment of Epilepsy |
| December 6 |
Theravance Announces Positive Topline Results In Phase 3 Telavancin
Hospital-Acquired Pneumonia Program |
| December 6 |
Cyclacel Pharmaceuticals to Present Sapacitabine Phase I data at US
American Society of Hematology Conference |
| December 6 |
Pharmion to Present Clinical Data on Key Hematology Products at
American Society of Hematology (ASH) Annual Meeting |
| December 6 |
Proteolix Announces Clinical Results With Carfilzomib to be
Reported at ASH 2007 Annual Meeting |
| December 6 |
SIGA Completes 21 Day Multi-Dose Human Clinical Safety and
Dose-Ranging Trial of Its Lead Smallpox Drug ST-246 |
| December 6 |
Remoxy Meets Primary Endpoint in Pivotal Phase III Study |
| December 6 |
Procrit (Epoetin Alfa) Data to be Presented at American Society of
Hematology Annual Meeting |
| December 7 |
Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) and
PNH at the 2007 American Society of Hematology (ASH) Annual Meeting |
| December 7 |
Catalyst Pharmaceutical Partners Announces Positive Phase II Trial
Results for Vigabatrin in the Treatment of Cocaine Addiction |
| December 7 |
The International Myeloma Foundation Says Major Medical Conference
Points to Improved Treatment and Survival Options for Blood Cancers |
| December 7 |
Xencor Presents Findings on New Aspect of its Fc Technology
Targeting Autoimmune Disease |
| December 7 |
Access Pharmaceuticals Demonstrates Ability to Significantly Reduce
Glucose Levels in Pre-clinical Testing of Cobalamin Oral Insulin |
| December 7 |
Acusphere Announces that Imagify Safety and ECHO Reader Training
Data Will Be Presented at EuroEcho 2007 |
| December 7 |
Acologix Presents Preclinical Data on Cartilage Regeneration by
AC-100 at the OARSI 2007 World Congress on Osteoarthritis |
| December 7 |
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to
be Presented at the Upcoming American Society of Hematology Meeting
in Atlanta, Georgia |
| December 7 |
New Taxotere (docetaxel) Injection Concentrate Data to be Presented
at the 30th Annual San Antonio Breast Cancer Symposium (SABCS) |
| December 10 |
XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C
Virus Small Molecule Program at Hep Dart 2007 - an International
Scientific Conference on Viral Hepatitis |
| December 10 |
Preliminary Results from VioQuest Pharmaceuticals' Phase I Trial of
Novel Akt Inhibitor VQD-002 in Patients with Advanced Leukemias
Demonstrate Promising Clinical Activity |
| December 10 |
BioCryst Announces Presentation of Data Detailing Synergistic
Activity of Forodesine HCl With Bendamustine in Chronic Lymphocytic
Leukemia (CLL) |
| December 10 |
Micromet and MedImmune Present New Clinical Data for MT103 at the
American Society of Hematology Annual Meeting Suggesting Potent
Single-Agent Activity in Patients with Relapsed Mantle Cell and
Follicular Lymphoma |
| December 10 |
EntreMed Presents Results for Its Lead Aurora Kinase-Angiogenesis
Inhibitor |
| December 10 |
Sangamo BioSciences Announces Presentation of Data for ZFP
Therapeutic for Glioblastoma at American Society for Hematology
Meeting |
| December 10 |
Osiris Therapeutics Reports Positive Results for Prochymal as a
Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host
Disease |
| December 10 |
ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in
Combination with Rituxan in B Cell Lymphoma |
| December 10 |
Dermatologic Surgery Journal Publishes Landmark Study Showing
Positive Five-Year Effects of ArteFill for Smile Lines |
| December 10 |
Vion Pharmaceuticals Presents Preliminary Data from its Pivotal
Phase II Trial of Cloretazine (VNP40101M) in Acute Myelogenous
Leukemia at ASH Annual Meeting |
| December 10 |
EpiCept Releases New Data Demonstrating Prolonged Five-Year
Leukemia-Free Survival for AML Patients Treated with Ceplene + IL-2 |
| December 10 |
Seattle Genetics Reports Multiple Complete Remissions With SGN-33
in Acute Myeloid Leukemia at ASH |
| December 10 |
Pharmacyclics Announces Presentation of Results from Phase 1/2
Trial of Xcytrin Plus Zevalin and Preclinical Data with Novel BTK
and HDAC Inhibitors |
| December 10 |
Innovative Research Advances Stem Cell and Bone Marrow
Transplantation |
| December 10 |
Xencor Data from Pre-clinical XmAb Antibody Studies Presented at
American Society of Hematology Meeting |
| December 10 |
Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated
with Reduced Hospital Costs of Venous Thromboembolism (VTE)
Treatment Compared with Unfractioned Heparin (UFH) |
| December 10 |
Genasense Plus Chemotherapy Is Associated With Prolonged Survival
in Patients With Relapsed/Refractory CLL Who Achieve Complete
Remission |
| December 10 |
DelSite Nasal Powder Technology Could Reduce Recently Reported
Waste in Federal Vaccine Program |
| December 10 |
Avalon Pharmaceuticals Announces their Beta-catenin Inhibitors
Demonstrate Potent Cytotoxic Effects in Multiple Myeloma |
| December 10 |
ASH presentation supports Antisoma's phase II trial in AML |
| December 10 |
ChemGenex Investigators Report Activity of Omacetaxine in
Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I
Mutation |
| December 10 |
Preclinical Studies Show Promise for Novel Antibody Therapy to
Treat Acute Myeloid Leukemia (AML) |
| December 10 |
Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data
on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory
Multiple Myeloma at 49th Annual Meeting of American Society of
Hematology |
| December 10 |
Enzon Presents New PEG-SN38 Preclinical Data at ASH |
| December 10 |
Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral
Prodrug of Tezampanel, May be Effective in Treating Acute Migraine
Headache |
| December 10 |
TREANDA Significantly Improves Clinical Outcomes in Patients with
Chronic Lymphocytic Leukemia Compared to Chlorambucil |
| December 10 |
Data Indicate That SuperGen's Lead JAK2 Kinase Inhibitors Prevent
Cancer Cell Proliferation in Non-clinical Models |
| December 10 |
Speedel Announces Start of SPP635 Phase IIa Trial in Diabetic
Patients |
| December 10 |
Avastin is Leading the Way for New Targeted Therapies to Replace
Current Cytotoxic Agents as Driving Force in Non-Small-Cell Lung
Cancer Market |
| December 10 |
Treanda Demonstrates Substantial Efficacy in Patients with Relapsed
Indolent Non-Hodgkin's Lymphoma |
| December 10 |
SuperGen's Novel Hypomethylating Agent Highlighted at American
Society of Hematology Annual Meeting |
| December 10 |
Genitope Corporation Presents New Data On Its Therapeutic
Monoclonal Antibodies To Potentially Treat B-Cell Malignancies |
| December 10 |
Gloucester Pharmaceuticals Announces Positive Interim Results of
Phase I/II Study in Patients with Multiple Myeloma at the 2007
American Society of Hematology (ASH) Annual Meeting |
| December 10 |
Gloucester Pharmaceuticals Reports Clinically Significant Responses
in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the
2007 American Society of Hematology (ASH) Annual Meeting |
| December 10 |
EntreMed Presents Results for ENMD-1198 and Vincristine in
Preclinical Leukemia Models |
| December 10 |
Long-Term Soliris Therapy Improved or Stabilized Kidney Function in
Patients With PNH |
| December 10 |
CSL Behring Study in Animal Models Shows Feasibility of Developing
a Half-Life Extended Recombinant FVIIa that Retains Biologic
Activity |
| December 10 |
New Study Shows Levitra Successfully Treats Erectile Dysfunction
(ED) in Men with Dyslipidemia, Including High Cholesterol |
| December 10 |
Celator Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity
in Leukemia Patients |
| December 10 |
Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in
Preventing Venous Thromboembolism After Major Orthopedic Surgery |
| December 10 |
Long-Term Safety and Efficacy Data on Promacta (Eltrombopag)
Presented at American Society of Hematology Annual Meeting |
| December 10 |
Innovive Pharmaceuticals Presents Phase I Data on INNO-406 for
Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous
Leukemia at ASH |
| December 10 |
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel
Selective Inhibitor of JAK2 |
| December 10 |
'Roche to announce new breast cancer data pointing to better
survival chances and potential for cure' |
| December 10 |
Epratuzmab Plus Rituximab Produce Durable Complete Responses in
Lymphoma |
| December 10 |
New Phase 2 Data for Non-EPO Treatment of Anemia |
| December 10 |
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic
Potential for the Treatment of Myeloproliferative and Other
Hematological Disorders |
| December 10 |
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in
Patients With Relapsed or Refractory Acute Leukemias; Data
Presented in Oral Session at 49th Annual Meeting of the American
Society of Hematology |
| December 10 |
Pivotal Phase 3 Nplate Study in Non-Splenectomized Patients Met
Primary Endpoints |
| December 10 |
Studies Show Effectiveness of Euflexxa in Treating Knee
Osteoarthritis and Reducing the Pain that Interferes with Daily
Activities |
| December 10 |
Gentler Chemotherapy Before Blood Stem Cell Transplant Causes
Long-Term Complete Remission in Relapsed Follicular Lymphoma
Patients |
| December 10 |
Xanthus' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute
Myeloid Leukemia |
| December 10 |
Pivotal Phase 3 NPLATE Study in Non-Splenectomized Patients Met
Primary Endpoints |
| December 10 |
Pharmion and MethylGene Present Favorable Clinical Data From
Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes
and Acute Myelogenous Leukemia at The 49th American Society of
Hematology (ASH) Meeting |
| December 10 |
Velcade (Bortezomib) for Injection Based Therapy Produced
Significant Complete Remission Rates Pre- and Post-Transplantation
in IFM Phase III Front-Line Multiple Myeloma Trial |
| December 10 |
Data Presented At The American Society Of Hematology 49th Meeting
Demonstrate That Incyte's Novel JAK Inhibitor, INCB18424, Provides
Rapid and Profound Clinical Benefits in Myelofibrosis Patients |
| December 11 |
ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data |
| December 11 |
ThromboGenics Presents Results of the Phase I Trial of TB-402 at
the Prestigious American Society of Hematology Annual Meeting |
| December 11 |
Poll of Infection Prevention and Control Professionals Reveals MRSA
Prevention Progress Six Months After National Survey |
| December 11 |
Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line
Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results
Presented at American Society of Hematology (ASH) Annual Meeting |
| December 11 |
Dacogen (Decitabine) for Injection Data Presented at the American
Society of Hematology (ASH) 49th Annual Meeting and Exposition |
| December 11 |
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART |
| December 11 |
AVAX Technologies Announces Successful Completion of Phase I / II
Study of MVax in Patients with Stage 3 and 4 Melanoma |
| December 11 |
Modeling Simulation Predicts Potential Negative Impact on U.S.
Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia |
| December 11 |
CuraGen and TopoTarget Report Belinostat Results Presented at ASH
and Provide Regulatory Update Following End-of-Phase II Meeting
with FDA |
| December 11 |
Aspect Medical Systems Announces Positive Results of BRITE Major
Depression National Study |
| December 11 |
ChemGenex Investigators Report Omacetaxine Effective in Killing CML
Stem Cells in Animal Model Studies |
| December 11 |
ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic
Side Effects for the Treatment of Colorectal Cancer, Other Types of
Solid Tumors |
| December 11 |
MDS Patients on Five-Day Vidaza Dosing Schedules Achieve
Transfusion Independence Consistent with Seven-day Schedule |
| December 11 |
Top-Line Data Available from Three Ipilimumab Pivotal Trials in
Patients with Advanced Metastatic Melanoma |
| December 11 |
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and
Minimal Transfusion Support Have Significant Disease Burden;
Soliris Therapy Provided Clinical Improvements in PNH Patients
Regardless of Disease Severity |
| December 11 |
Panacos Announces Results of Bevirimat 350 mg Cohort, Data Support
Further Dose Escalation in Phase 2b Study |
| December 11 |
The International Myeloma Foundation Says New Findings Reported at
Global Cancer Conference Require New Ways to Evaluate Treatments |
| December 11 |
Sunesis Pharmaceuticals Reports Positive Data at ASH |
| December 11 |
Early Phase II Results Show Bosutinib Safe, Effective for CML |
| December 11 |
New Phase III Trial Shows Positive Outcome of lacosamide in
Patients with Diabetic Neuropathic Pain |
| December 11 |
MMRC Genomics Initiative Selected for Two Presentations At American
Society of Hematology Annual Meeting |
| December 11 |
Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated |
| December 11 |
JWCI Researchers Identify Epigenomic Test That Could Improve
Treatment for Specific Gastric Cancers |
| December 11 |
Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb
MRSA |
| December 12 |
Ceregene Presents Long-term Follow-up From Phase 1 Trial of
CERE-120 in Parkinson's Disease |
| December 12 |
Once-Daily Exjade Shown to Remove Toxic Iron From the Heart and
Liver, According to Data Presented at ASH |
| December 12 |
GlaxoSmithKline Responds to JAMA Article on the ICES
Thiazolidinediones and Cardiovascular Outcomes in Older Patients
with Diabetes |
| December 12 |
Results from Biovitrum's Phase II Clinical Trial of Novel Pain
Treatment is Expected to be Presented in Beginning of Second
Quarter 2008 |
| December 12 |
Peplin Announces Positive Results of Phase IIa AK Trial |
| December 12 |
Invega Shows Favorable Long-Term Safety Profile in a One-Year Study
of Patients With Schizophrenia |
| December 12 |
New Phase 3 Data Showed Pristiq Significantly Reduced Symptoms of
Major Depressive Disorder Versus Placebo |
| December 12 |
Scientists Develop New Drug to Outflank Cancer Resistance |
| December 12 |
Nymox Reports Update on NX-1207 Study Results, Marketing Plans and
Activities |
| December 12 |
Mayo Clinic Proceedings Article Offers New Data About the Impact of
the Shingles Virus on Healthy Adults |
| December 12 |
Pioglitazone Lowers Cardiovascular Risk in Diabetic Patients with
Kidney Disease |
| December 12 |
Regulus Therapeutics and Collaborators Discover Role of Viral
microRNAs in Cancer and Identify First-Ever Example of a Viral
microRNA Oncogene |
| December 13 |
Puricase (pegloticase) Meets Pre-Specified Primary Efficacy
Endpoint in Two Replicate Phase 3 Studies |
| December 13 |
Chroma Announces Positive Phase I Efficacy Data for Novel Cancer
Therapy CHR-2797 |
| December 13 |
Rigel's R788 Demonstrates Significant Improvement in Rheumatoid
Arthritis in Phase 2 Clinical Study |
| December 13 |
Vanda Presents Phase III Iloperidone Efficacy Data |
| December 13 |
Savient Pharmaceuticals to Release Top-Line Results from Puricase
Phase 3 Trials in Treatment-Failure Gout on December 13, 2007 |
| December 13 |
Radiesse Provides Greater Patient Satisfaction Than Either Juvederm
or Perlane as Reported in a 205-Patient Clinical Trial Published in
the Journal of Dermatologic Surgery |
| December 13 |
Neose Announces Presentation of GlycoPEGylated Factor VIIa Data at
the American Society of Hematology Annual Meeting |
| December 13 |
Genzyme Study of Myozyme for Late-Onset Pompe Patients Meets
Co-Primary Efficacy Endpoints |
| December 13 |
Genzyme Study of Myozyme for Late-Onset Pompe Patients Meets
Co-Primary Efficacy Endpoints |
| December 13 |
Sirtris Pharmaceuticals' SIRT1 Activator Controls Glucose as Well
as a DPP-4 inhibitor in a Pre-Clinical Model of Type 2 Diabetes |
| December 13 |
Patients Given Sunitinib Need Close Monitoring for Cardiac Problems |
| December 13 |
High-Dose Chemotherapy, Autologous Stem Cell Transplantation Shows
Little or No Survival Benefit as Adjuvant Therapy for Node-Positive
Breast Cancer |
| December 13 |
Taxotere-Based Chemotherapy Significantly Improved Overall Survival
Compared With Standard Anthracycline-Based Chemotherapy in Early
Stage Breast Cancer |
| December 13 |
WILEX Announces Positive Result of the Interim Analysis for
Futility of its Phase III ARISER Trial with Rencarex |
| December 13 |
Iloperidone Phase III Clinical Data Demonstrate Efficacy and
Favorable Safety and Tolerability Profile |
| December 13 |
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study |
| December 13 |
PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After
Treatment With Drug-Eluting Stents |
| December 13 |
Early Results Show Promise in Reducing Side Effects from
Anastrozole |
| December 14 |
Javelin Pharmaceuticals Announces Successful Dyloject Pivotal US
Phase 3 Trial Top-Line Results at New York City Analyst Day |
| December 14 |
Data Presented at 2007 ASH Meeting Demonstrate Activity of
Forodesine HCl as a Single Agent or in Combination With
Bendamustine in Certain Types of Leukemia and Lymphoma |
| December 14 |
HERmark Assay Results in Metastatic Breast Cancer Presented at the
San Antonio Breast Cancer Symposium |
| December 14 |
Inhibitex Reports Favorable Results from First Clinical Trial of
FV-100 |
| December 14 |
Multigene Test Predicts Who Could Avoid Chemotherapy Despite
Positive Lymph Nodes in Early Breast Cancer |
| December 14 |
SABCS: AI Bone Loss Significantly Less With Zometa |
| December 17 |
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit
in Patients With Trastuzumab-Refractory Metastatic Breast Cancer |
| December 17 |
Xeloda, Taxotere and Herceptin Combination Study Suggests Clinical
Benefit in Invasive Breast Cancer with Shortened Treatment Cycle |
| December 17 |
Data Presented at the 30th San Antonio Breast Cancer Symposium
Supports Further Development of INCB7839 as a New Oral Treatment
for Breast Cancer |
| December 17 |
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment |
| December 17 |
Breast Cancer Patients and Oncologists Highly Satisfied with
Communication, Yet Disagree on Conversation Priorities |
| December 17 |
Novavax Announces Preclinical Results for Seasonal Influenza
Vaccine Program |
| December 17 |
Pivotal Phase 3 Data Show Denosumab Increased Bone Density
Throughout Skeleton in Non-Metastatic Breast Cancer Patients on
Adjuvant Aromatase Inhibitor Therapy |
| December 17 |
Adipose-Derived Stem Cells Show Promise in Breast Reconstruction |
| December 17 |
Anastrozole Confirmed Superior in Breast Cancer Prevention |
| December 17 |
Data Show Arimidex (Anastrozole) Continues To Be Superior to
Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With
Early Breast Cancer |
| December 17 |
Endo Announces Positive Results From Interim Analysis of Rapinyl
Phase III Clinical Trial |
| December 17 |
PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel
VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer
Symposium |
| December 17 |
Actelion Provides Update On Bosentan in Metastatic Melanoma |
| December 17 |
Orexo's Partner Endo Announces Positive Results from Interim
Analysis of Rapinyl Phase III Clinical Trial |
| December 17 |
GlaxoSmithKline Announces Data on Tykerb (Lapatinib) Plus
Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain
Metastases |
| December 17 |
Dynogen Announces Positive Results in Phase 2 IBS-d Study |
| December 17 |
Weitz & Luxenberg Recognizes New Advance in Mesothelioma
Treatment |
| December 17 |
Pilot Study Opens the Door for Avastin Use in Curative Setting for
Women With Breast Cancer |
| December 17 |
Phosphagenics Ltd Announce Successful Transdermal Oxycodone
Clinical Trial Results |
| December 17 |
Scientists Find Bowel Cancer Genes That Triple Risk |
| December 17 |
Ablynx reports positive Phase I results for its anti-thrombotic
NanobodyR, ALX-0081 |
| December 17 |
New Study Results Show Asenapine More Effective Than Placebo in the
Treatment of Acute Schizophrenia |
| December 17 |
New Drug Combination is Able to Eradicate Breast Metastases in Mice |
| December 18 |
Epix Pharmaceuticals Reports Compelling Clinical Results for
PRX-03140 in Alzheimer's Disease; Statistically Significant
Improvement in Cognitive Function Achieved Within Two Weeks |
| December 18 |
New Approach to Treating Anthrax Significantly Improves Survival
Rates in Pivotal Efficacy Studies |
| December 18 |
Wilex Updates the Status of the Rencarex Phase III-Ariser Study
Following the Positive Interim Analysis for Futility |
| December 18 |
Results of Vasogen's Phase III ACCLAIM Trial Accepted for
Publication in The Lancet |
| December 18 |
Durect Announces Positive Eladur Phase IIa Study Results |
| December 18 |
Psoriasis Study Showing Increased Risk of Death Underscores Need
for More Research, Group Says |
| December 19 |
Javelin Pharmaceuticals Announces Peer-Reviewed Publication of
Successful Postoperative Pain Trial with PMI-100/150 (Intranasal
Ketamine) in International Journal, ''Acute Pain'' |
| December 19 |
Intra-Cellular Therapies Presents Preclinical Data From
Schizophrenia and Sleep Maintenance Programs |
| December 19 |
Researchers Train the Immune System to Deliver Virus That Destroys
Cancer in Lab Models |
| December 19 |
BioLineRx Announces Presentation of Pre-Clinical Data Demonstrating
that BL-2030 Reduces Tumor Growth and Prevents Metastasis in Model
of Prostate Cancer |
| December 19 |
Biovitrum Has Successfully Completed the First Phase I Trial of its
5-HT6 Receptor Antagonist (BVT.74316) |
| December 19 |
Unigene States That New Government Study Reports That Many
Osteoporosis Medications Prevent Fractures, but None is Proven Best |
| December 20 |
Novavax Announces Favorable Interim Results from Human Clinical
Trial for Its Pandemic Influenza Vaccine Program |
| December 20 |
Ceragenin Compound Demonstrates Potent Activity Against Multidrug
Resistant Bacterial Strains of Pseudomonas |
| December 20 |
FASgen Announces New Discovery for Treatment of Stroke |
| December 20 |
Amicus Therapeutics Announces Positive Results From Phase 2
Clinical Trials of Amigal for Fabry Disease |
| December 20 |
Collegium Pharmaceutical Inc. Announces Final Study Results of its
Successfully Completed Proof of Concept Study for its Abuse
Deterrent Sustained Release Opioid Product |
| December 20 |
Topline Results Announced from a Phase 2 Study in Advanced Melonoma
of Investigational Anti-Cancer Drug AZD6244 (ARRY-886) |
| December 20 |
Study Reaffirms Superiority of Trofile Assay |
| December 20 |
Study Linking Increased Risk of Death to Severe Psoriasis a Call to
Action |
| December 20 |
Breakthrough in Pulmonary Drug Delivery will Bring Numerous
In-Hospital Treatments to the Home |
| December 20 |
A New Treatment Option for Patients with Renal Cancer |
| December 20 |
Genitope Corporation to Host Conference Call to Discuss Initial
Results of Phase 3 Clinical Trial |
| December 21 |
Genitope Corporation Reports Initial Results of Phase 3 Clinical
Trial of MyVax(R) Personalized Immunotherapy |
| December 26 |
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic
Influenza (H5N1) Whole Viron Vaccine |
| December 27 |
VGX Pharmaceuticals Announces Successful Completion of the First
Human Study to Assess the Tolerability of Cellectra Electroporator |
| December 27 |
Leiden University Medical Center and Prosensa B.V. Announce New
England Journal of Medicine Publication of First Successful
Clinical Study with RNA-based Therapeutic PRO051 in Duchenne
Muscular Dystrophy |
| December 28 |
FASgen Announces New Research Discoveries in Lung Cancer |
| December 28 |
Publication of the INSPIRE study results |
